Inovio expands partnership with advaccine to conduct global phase 3 efficacy trial of covid-19 dna vaccine candidate, ino-4800

Plymouth meeting, pa., june 8, 2021 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on bringing to market precisely designed dna medicines to treat and protect people from infectious diseases, cancer, and hpv-associated diseases, today announced an expansion of its previously announced partnership with advaccine biopharmaceuticals suzhou co., ltd.
INO Ratings Summary
INO Quant Ranking